mfn-cus-2020 | Nanologica

Extended Collaboration with Crop Protection Company

30 October, 2020

Nanologica has signed an agreement for continued collaboration with the global agricultural company that Nanologica has been working with. The extended agreement includes the formulation of another new active ingredient for plant protection using Nanologica’s technology. The value of the agreement amounts to approximately MSEK 1,3. In September 2017, Nanologica entered into an agreement with a global agricultural company specialized in crop protection, with the purpose of improving the formulation of an active ingredient

Nanologica’s patent granted in Europe

30 September, 2020

The European Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. The patent protects the Company’s technology platform NLAB Spiro™ by giving exclusivity on the stated method for producing particles loaded with active pharmaceutical ingredients for lung delivery, among others. ” This patent is a milestone for Nanologica, and it is pleasing that we now

Nanologica Signs Agreement with Vicore Pharma Worth up to MSEK 8

26 June, 2020

Nanologica AB has within the project with Vicore Pharma been assigned to commence preparative work for the manufacturing of GMP classified material. The agreement is worth up to MSEK 8. The VP02 project aims to deliver an API locally in the lung by formulating it using Nanologica’s technology platform for inhalation, NLAB Spiro™. The platform is constituted of biologically degradable nanoporous microspheres that can be loaded with APIs. The method can potentially maximize the

Nanologica Engages Per Möller as Scientific Advisor within Preparative Chromatography

25 June, 2020

Nanologica AB has engaged Per Möller, a distinguished scientist with industrial experience, for the purpose of having a qualified advisor for strategic and tactical issues regarding Nanologica’s business field of preparative chromatography. Per Möller has a background as an organic chemist in the lab of Nobel Prize laureate Arvid Carlsson. He has more than 35 years’ experience from the chromatography area including the chromatographic resin business, drug discovery, scaling-up and GMP production of biological pharmaceuticals.

Nanologica Signs Distributor Agreement for the American, Canadian and European Market

3 March, 2020

Nanologica AB has signed a distribution agreement with American International Chemical LLC (AIC) for the American, Canadian and European market to further expand Nanologica’s geographical market coverage. Through the agreement, AIC will market and resell Nanologica’s products for analytical chromatography in the US, Canada and Europe. ” We have had discussions and some collaborations with AIC regarding the chromatography market in the US and North American regions for some time. With Nanologica’s product development, both

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.